XGEVA (denosumab) is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

XGEVA is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.

Hypocalcemia: Severe hypocalcemia can occur in patients receiving Xgeva. Correct hypocalcemia prior to initiating Xgeva. Monitor calcium levels and adequately supplement all patients with calcium and vitamin D

Osteonecrosis of the jaw can occur in patients receiving Xgeva. Perform an oral examination prior to starting Xgeva. Monitor for symptoms. Avoid invasive dental procedures during treatment with Xgeva